Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wei, Tingting ^a   Zhao, Liangcai ^a   Jia, Jianmin ^a   Xia, Huanhuan ^a   Du, Yao ^a   Lin, Qiuting ^a   Lin, Xiaodong ^a   Ye, Xinjian ^a   Yan, Zhihan ^a   Gao, Hongchang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACONITIC ACID; ACYL COENZYME A; ALLANTOIN; AMIDASE; BIOLOGICAL MARKER; DIMETHYLARGININASE; FATTY ACID; GUANOSINE TRIPHOSPHATE; LEPTIN RECEPTOR; METHYLAMINE;

ANIMAL; C57BL MOUSE; DEFICIENCY; DIABETIC NEPHROPATHIES; DISCRIMINANT ANALYSIS; GENETICS; KIDNEY; KNOCKOUT MOUSE; MALE; METABOLISM; METABOLOMICS; MOUSE; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; URINE;

ACONITIC ACID; ACYL COENZYME A; ALLANTOIN; AMIDOHYDROLASES; ANIMALS; BIOMARKERS; DIABETIC NEPHROPATHIES; DISCRIMINANT ANALYSIS; FATTY ACIDS; GUANOSINE TRIPHOSPHATE; KIDNEY; MALE; METABOLOMICS; METHYLAMINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PRINCIPAL COMPONENT ANALYSIS; RECEPTORS, LEPTIN;

EID: 84936852427     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11998     Document Type: Article

References (46)

1. Shao, N. et al. Relationship between Oxidant/Antioxidant Markers and Severity of Microalbuminuria in the Early Stage of Nephropathy in Type 2 Diabetic Patients. J. Diabetes Res. 2013, 232404 (2013).
2. Kanwar, Y. S., Sun, L., Xie, P., Liu, F. Y. & Chen, S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6, 395-423 (2011).
3. Shockcor, J. P. & Holmes, E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2, 35-51 (2002).
4. Nicholson, J. K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2, 52 (2006).
5. Nicholson, J. K., Lindon, J. C. & Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
6. Psihogios, N. G., Gazi, I. F., Elisaf, M. S., Seferiadis, K. I. & Bairaktari, E. T. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 21, 195-207 (2008).
7. 1H-NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am. J. Physiol. Renal Physiol. 300, F947-956 (2011).
8. 1H-NMR based metabonomic approach. Mol. Biosyst. 10, 686-693 (2014).
9. Guan, M. et al. Systemic perturbations of key metabolites in diabetic rats during the evolution of diabetes studied by urine metabonomics. PLoS One 8, e60409 (2013).
10. Li, M. et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 304, F1317-1324 (2013).
11. 1H NMR-based metabonomic analysis of serum and urine in a nonhuman primate model of diabetic nephropathy. Mol. Biosyst. 9, 2645-2652 (2013).
12. Sharma, K., McCue, P. & Dunn, S. R. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Renal Physiol. 284, F1138-1144 (2003).
13. Hu, Y. et al. Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus. BMC Med. Genomics 2, 41 (2009).
14. 1H NMR spectroscopic urinalysis. Hypertens Res. 35, 404-412 (2012).
15. Teimoury, A., Iraj, B., Heidari-Beni, M., Amini, M. & Hosseiny, S. M. Why 24-h Urine Albumin Excretion Rate Method Still is Used for Screening of Diabetic Nephropathy in Isfahan Laboratories? Int. J. Prev. Med. 5, 341-347 (2014).
16. Boudonck, K. J. et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37, 280-292 (2009).
17. Zuppi, C. et al. Proton nuclear magnetic resonance spectral profiles of urine from children and adolescents with type 1 diabetes. Clin. Chem. 48, 660-662 (2002).
18. Briggs, J. P., Levitt, M. F. & Abramson, R. G. Renal excretion of allantoin in rats: a micropuncture and clearance study. Am. J. Physiol. 233, F373-381 (1977).
19. Salek, R. M. et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics 29, 99-108 (2007).
20. Peti-Peterdi, J. High glucose and renin release: the role of succinate and GPR91. Kidney Int. 78, 1214-1217 (2010).
21. Messenger, J., Clark, S., Massick, S. & Bechtel, M. A review of trimethylaminuria: (fish odor syndrome). J. Clin. Aesthet. Dermatol. 6, 45-48 (2013).
22. Zhao, L. C. et al. A metabonomic comparison of urinary changes in Zucker and GK rats. J. Biomed. Biotechnol. 2010, 431894 (2010).
23. Chobanyan, K., Mitschke, A., Gutzki, F. M., Stichtenoth, D. O. & Tsikas, D. Accurate quantification of dimethylamine (DMA) in human plasma and serum by GC-MS and GC-tandem MS as pentafluorobenzamide derivative in the positive-ion chemical ionization mode. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 851, 240-249 (2007).
24. Brinkmann, S. J., de Boer, M. C., Buijs, N. & van Leeuwen, P. A. Asymmetric dimethylarginine and critical illness. Curr. Opin. Clin. Nutr. Metab. Care 17, 90-97 (2014).
25. Chobanyan-Jurgens, K. et al. Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II. Amino Acids 43, 805-811 (2012).
26. Pullamsetti, S. S. et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci. Transl. Med. 3, 87ra53 (2011).
27. Bal, F. et al. Antidiabetic drug metformin is effective on the metabolism of asymmetric dimethylarginine in experimental liver injury. Diabetes Res. Clin. Pract. 106, 295-302 (2014).
28. Sasser, J. M., Cunningham, M. W., Jr. & Baylis, C. Serelaxin reduces Oxidative Stress and Asymmetric Dimethylarginine in Angiotensin II Induced Hypertension. Am. J. Physiol. Renal Physiol. 307, F1355-1362 (2014).
29. 3 in rats. J. Inorg. Biochem. 99, 2151-2160 (2005).
30. Fu, Z., Runquist, J. A., Montgomery, C., Miziorko, H. M. & Kim, J. J. Functional insights into human HMG-CoA lyase from structures of Acyl-CoA-containing ternary complexes. J. Biol. Chem. 285, 26341-26349 (2010).
31. Nakagawa, S., Kojima, Y., Sekino, K. & Yamato, S. Effect of polyphenols on 3-hydroxy-3-methylglutaryl-coenzyme A lyase activity in human hepatoma HepG2 cell extracts. Biol. Pharm. Bull. 36, 1902-1906 (2013).
32. Wolf, H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand. J. Clin. Lab. Invest. Suppl. 136, 1-186 (1974).
33. 1H-NMR spectral patterns. Biomarkers 9, 364-385 (2004).
34. Orszaghova, Z. et al. Effects of N1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus. Redox Rep. 17, 1-7 (2012).
35. Dagher, P. C. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 66, 506-509 (2004).
36. Ren, J. Hope or hype: The obsession for tetrahydrobiopterin and GTP cyclohydrolase I (GTPCH I) in cardiovascular medicine. J. Cardiothorac. Renal Res. 1, 15-21 (2006).
37. Du, J. et al. Identification of proteins interacting with GTP cyclohydrolase I. Biochem. Biophys. Res. Commun. 385, 143-147 (2009).
38. Carlomagno, G., De Grazia, S., Unfer, V. & Manna, F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin. Drug Deliv. 9, 267-271 (2012).
39. Kanwar, Y. S. et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 233, 4-11 (2008).
40. Prabhu, K. S., Arner, R. J., Vunta, H. & Reddy, C. C. Up-regulation of human myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular epithelial cells. J. Biol. Chem. 280, 19895-19901 (2005).
41. Ghosh, S. et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am. J. Physiol. Renal Physiol. 296, F700-708 (2009).
42. Xiao, C., Hao, F., Qin, X., Wang, Y. & Tang, H. An optimized buffer system for NMR-based urinary metabonomics with effective pH control, chemical shift consistency and dilution minimization. Analyst 134, 916-925 (2009).
43. 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal. Biochem. 383, 76-84 (2008).
44. Westerhuis, J. A., van Velzen, E. J., Hoefsloot, H. C. & Smilde, A. K. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics 6, 119-128 (2010).
45. 1H NMR spectroscopy. J. Proteome Res. 6, 3456-3464 (2007).
46. 1H NMR spectroscopic metabonomic studies. Anal. Chem. 77, 517-526 (2005).